Fellowship · Philadelphia, PA
Sponsored by Temple University Hospital
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 349 citations · Gina Mantia-Smaldone
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 85 citations · Gina Mantia-Smaldone
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 55 citations · Gina Mantia-Smaldone
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gynecologic oncology · 2023 · 107 citations · Gina Mantia-Smaldone
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet (London, England) · 2021 · 177 citations · Gina Mantia-Smaldone
Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 25 citations ·
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Gynecologic oncology · 2024 · 36 citations · Gina Mantia-Smaldone
Uterine serous carcinoma: key advances and novel treatment approaches.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2021 · 62 citations · James Ferriss